Trial reportPsychopharmacology2006
Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder.
Trial report in Psychopharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- The Impact of Development on Antidepressant and Placebo Response in Anxiety Disorders: A Bayesian Hierarchical Meta-Analytic Examination of Randomized Controlled Trials in Children, Adolescents, and Adults.Journal of child and adolescent psychopharmacology · 2024Pooled it
- Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2022Pooled it
- 5-HTTLPR moderates naltrexone and psychosocial treatment responses in heavy drinking men who have sex with men.Alcoholism, clinical and experimental research · 2014Trial
- Influence of RGS2 on sertraline treatment for social anxiety disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.The pharmacogenomics journal · 2013Trial
- Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder.PloS one · 2013Trial
- Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study.Genes, brain, and behavior · 2012Trial
- Serotonin transporter polymorphism modulates N-back task performance and fMRI BOLD signal intensity in healthy women.PloS one · 2012Trial
- The short (S) allele of the serotonin transporter polymorphism and acute tryptophan depletion both increase impulsivity in men.Neuroscience letters · 2010Trial
- A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2008Trial
- A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.Gastroenterology · 2008Trial
- Gut microbiota in anxiety and depression: mechanisms, drug interactions, and therapeutic implications.Pharmacological reports : PR · 2025Review
- A Combinational Therapy for Preventing and Delaying the Onset of Alzheimer's Disease: A Focus on Probiotic and Vitamin Co-Supplementation.Antioxidants (Basel, Switzerland) · 2024Review
- Emotional self-regulation, impulsivity, 5-HTTLPR and tobacco use behavior among psychiatric inpatients.Journal of affective disorders · 2022Article
- Methylation of the serotonin transporter gene moderates the depressive subjective effect of cocaine.Behavioural brain research · 2022Article
- Article
- Association of TPH1 and serotonin transporter genotypes with treatment response for suicidal ideation: a preliminary study.European archives of psychiatry and clinical neuroscience · 2020Article
- Trait Anxiety Mediated by Amygdala Serotonin Transporter in the Common Marmoset.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020Article
- From Probiotics to Psychobiotics: Live Beneficial Bacteria Which Act on the Brain-Gut Axis.Nutrients · 2019Review
- Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review.Current problems in pediatric and adolescent health care · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
objectivesTo determine whether variation in the serotonin transporter gene promoter (5HTTLPR) influences the efficacy of selective serotonin reuptake inhibitors (SSRIs) in generalized social anxiety disorder (GSAD).
methodsConsecutive series of N=32 patients with DSM-IV GSAD for whom DNA and standardized outcome data from a 12-week SSRI trial were available. After ensuring that neither clinical response [clinical global impression of change scale (CGI-C)] nor 5HTTLPR genotype was confounded by ethnicity or sex, we determined whether the number of copies (0, 1, or 2) of hi-risk alleles using either the diallelic L-S system or the triallelic La-Lg-S system, predicted response and change in Liebowitz social anxiety scale (LSAS) and brief social phobia scale (BSPS) scores during SSRI treatment.
resultsTwenty-one patients (66%) were responders to SSRI (i.e., CGI-C much or very much improved). A trend was seen for a linear association between 5HTTLPR genotype and likelihood of response to SSRI: diallelic classification L/L 7/8 (88%), L/S 12/18 (67%), S/S 2/6 (33%), p=0.051; triallelic classification L'/L' 4/5 (80%), L'/S' 14/19 (74%), S'/S' 3/8 (38%), p=0.093. Reduction in LSAS (and BSPS) scores during SSRI treatment was significantly (p<0.02) associated with 5HTTLPR genotype using either the diallelic or triallelic classification.
conclusionsVariation in a functional polymorphism known to influence serotonin reuptake is associated with SSRI response in patients with GSAD. Independent replication in larger samples is required before the predictive utility of this information can be confirmed and generalized to clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.